BOSTON: Changes in key biomarkers of Alzheimer’s disease during midlife may help identify those who will develop dementia years later, new research suggests.
The study focused on data gathered over 10 years and involved 169 cognitively normal research participants ages 45 to 75 when they entered the study. Each participant received a complete clinical, cognitive imaging, and cerebrospinal fluid biomarker analysis every three years, with a minimum of two evaluations.
At the participants’ initial assessments, researchers divided them into three age groups: early-middle age (45-54); mid-middle age (55- 64); and late-middle age (65-74).
The changes were more pronounced in people who carried a form of a gene that significantly increases the risk of Alzheimer’s disease.